Trial Radar AI | ||
|---|---|---|
De klinische studie NCT06610773 voor Humane papillomavirussen, mesenchymale stamcellen is rekruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag. | ||
Eén studie komt overeen met de filtercriteria
Kaartweergave
HUC-MSC for Treatment of High-risk HPV Infection Fase 1, Fase 2 60
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT06610773 onderzoekt behandeling bij Humane papillomavirussen, mesenchymale stamcellen. Deze Fase 1 Fase 2 interventioneel-studie heeft de status rekruterend. Het doel is om 60 deelnemers te includeren vanaf 1 maart 2024. De studie wordt geleid door Shanghai East Hospital en de voltooiing is gepland op 10 september 2026. Laatste update op ClinicalTrials.gov: 24 september 2024.
Beknopte samenvatting
To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.
Uitgebreide beschrijving
Cervical cancer is one of the most common malignant tumors of the female reproductive system with the highest incidence. Nearly 99.7% of cervical cancer is caused by HPV infection. Studies have shown that the persistent infection of high-risk human papillomavirus (HR-HPV) is an independent risk factor for cervical cancer which can lead to a 250-fold increased risk of high-grade cervical intraepithelial neoplasia (CIN...Toon meer
Officiële titel
Effectiveness and Safety of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of HPV High-risk Infection
Aandoeningen
Humane papillomavirussenmesenchymale stamcellenAndere studie-ID's
- DFSC-2024(CR)-001
- HX-2021-007 (Ander subsidie-/financieringsnummer) (Shanghai Shanghai East Hospital)
NCT-ID
Startdatum (Werkelijk)
2024-03-01
Laatste update geplaatst
2024-09-24
Verwachte einddatum
2026-09-10
Inschrijving (Geschat)
60
Studietype
Interventioneel
FASE
Fase 1
Fase 2
Fase 2
Status
Rekruterend
Trefwoorden
HPV
hUC-MSC
hUC-MSC
Primaire doel
Behandeling
Toewijzing
Gerandomiseerd
Interventiemodel
Parallel
Blindering
Geen (Open-label)
Armen / Interventies
| Deelnemersgroep/Studiearm | Interventie/Behandeling |
|---|---|
ExperimenteelExperimental group 1×10\^6/Kg UC-MSCs (resuspended in 100 mL normal saline containing 5% albumin) are infused intravenously to the high-risk HPV persistant infected patients at a controlled rate of 60-80 drops/min | hUC-MSCs 1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min. |
Placebo-comparatorControl group Normal saline containing 5% albumins are infused intravenously with an equal volume, similar suspension and appearance package as UC-MSCs to the high-risk HPV persistant infected patients at a controlled rate of 60-80 drops/min | Saline+albumin Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs |
Primaire uitkomst
Secundaire uitkomst
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Adverse events-The incidence rate of allergic reaction | The allergic reaction rate on the 1st day, 1st week, 4th week, 12th week, and 36th week after the infusion. | 1day,1st,4th,12th,and 36th week |
The 24 type HPV viral load | HPV24 genotypes test is classified from female genitourinary secretions and exfoliating cells of cervix by fluorescent PCR before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 4th week, 12th week, and 36th week after the infusion. | -28th~0day,4th,12th,and 36th week |
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
The percentage of CD3+ | The peripheral blood serum of the patients will be collected to detect the percentage（%）of CD3+ before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week, 12th and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The percentage of CD4+ | The peripheral blood serum of the patients will be collected to detect the percentage（%）of CD4+ before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week, 12th and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The percentage of CD8+ | The peripheral blood serum of the patients will be collected to detect the percentage（%） of CD8 before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week, 12th and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The percentage of CD19+ | The peripheral blood serum of the patients will be collected to detect the percentage（%）of CD19+ before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week, 12th and 36th week after the infusion | -28th~0day,1day,1st,4th,12th,and 36th week |
The percentage of CD16+/CD56+ | The peripheral blood serum of the patients will be collected to detect the percentage（%） of CD16+/CD56+ before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week, 12th and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The serum level of IFN-γ | The peripheral blood serum of the patients will be collected to detect the level of IFN-γ (pg/mL) before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 12th week, and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The serum level of IL-6 | The peripheral blood serum of the patients will be collected to detect the level of IL-6 (pg/mL) before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week,12th week, and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The serum level of IL-8 | The peripheral blood serum of the patients will be collected to detect the level of IL-8 (pg/mL) before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week,12th week, and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The serum level of IL-10 | The peripheral blood serum of the patients will be collected to detect the level of IL-10 (pg/mL) before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 4th week,12th week, and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
The serum level of TNF-α | The peripheral blood serum of the patients will be collected to detect the level of TNF-α (pg/mL) before the infusion of hUC-MSCs (Any day from 28th to 1st day) and on the 1st day, 1st week, 12th week, and 36th week after the infusion. | -28th~0day,1day,1st,4th,12th,and 36th week |
Deelname-assistent
Geschiktheidscriteria
Leeftijd van deelnemers
Volwassene
Minimumleeftijd
25 Years
Geslachten die in aanmerking komen voor de studie
Vrouw
- Women aged 25-60 with a sexual history of more than 2 years;
- Confirmed HPV infection by HPV-24 test;Patients diagnosed with high-risk human papillomavirus (HR-HPV) persistent infection; (note: the HR HPV: HPV 16/18/31/33/35/39/45/51/52/53/56/58/59/66/68; 15 types)
- The subjects were not participating in other clinical trials at the same time, and had no other anti-HPV drugs or intervention therapy recently;
- If the pregnancy test is negative and the subjects have fertility potential, they agree to use effective contraception during the study period and within 6 months of completion or termination of the study;
- Voluntarily participate in and agree to cooperate in accordance with the requirements of the program, and sign the informed consent.
- Women who are preparing for pregnancy, pregnancy or breastfeeding;
- Pathological diagnosis of high-grade squamous intraepithelial lesion (HSIL) or cervical cancer;
- Previous HPV vaccinations;
- A history of severe drug allergies, or allergies to stem cell products or other biologics;
- Previous cervical site physical therapy or related surgical history;
- Patients with severe immune dysfunction (such as AIDS, systemic lupus erythematosus and other immune system diseases or history of organ transplantation, malignant tumor chemotherapy history), serious cardiovascular, liver, kidney, nervous, hematopoietic system diseases or malignant tumors, or mental diseases;
- Recent use of other antiviral drugs, immunosuppressants, immunomodulators or steroid hormones that affect the immune system;
- Patients with acute genital tract inflammation or pelvic inflammation;
- Those who have participated in or are participating in clinical trials of other drugs within three months;
- Other conditions considered inappropriate by the investigator for inclusion in this clinical trial.
Shanghai East HospitalCentraal Contactpersoon
Contact: Jingjing Liu, M.D,.PH.D., 13795350828, [email protected]
1 Studielocaties in 1 landen
Shanghai Municipality
Shanghai Shanghai East Hospital, Tongji University School of Medicine, Shanghai, Shanghai Municipality, 200120, China
Fang Li, M.D.,PH.D., Contact, 13801986709, [email protected]
Fang Li, M.D.,PH.D., Contact
Zhongmin Liu, M.D.,PH.D., Contact
Rekruterend